Znomics has developed a proprietary technology platform that allows high throughput screening of complex biological pathways in vivo. The Znomics technology uses zebrafish for in vivo screening of small molecules because the pathways and genes that are involved in metabolic diseases and cancer are very similar to those in man. However, in vivo phenotypic screens can be done in high throughput in Zebrafish examining the effect of small molecules on an entire pathway.
Znomics is actively seeking pharma partners with whom it can develop additional small molecules for the treatment of diabetes/obesity and cancer.
Companies and academic scientists with specific project ideas are invited to contact us.
Alliances
Merck & Co., Inc.
See press release...
Academic Partners
Znomics has established relationships with scientists at more than 100 academic institutions worldwide, based on their acquisition of ZeneMark Library mutant fish lines. Examples include:
- Dana-Farber Cancer Institute
- Harvard University
- Johns Hopkins University
- Massachusetts General Hospital
- Max Planck Institute for Cell Biology and Genetics, Germany
- U.S. National Institutes of Health (NIH)
- Northwestern University
- Oregon Health and Science University
- Salk Institute
- Stanford University
- University of North Carolina, Chapel Hill
- University of California, San Francisco
- University of Iowa
- University of Munich, Germany
- University of Oregon
- University of Pennsylvania
- University of Pittsburgh
- University of Texas Health Science Center
- University of Utah
- University of Washington
- University of Wisconsin, Madison
- Washington University, St. Louis
|
 |
Fishing with Znomics — today’s catch means tomorrow’s treatments
In situ hybridization shows the expression of the insulin gene in the zebrafish pancreas. Both of the major drugs for type II diabetes, metformin and the thiazoladinediones, are active in the zebrafish. Thus, the zebrafish provides a unique model system for identification of new and
better drugs for diabetes treatment.
By fostering productive collaborative relationships with both commercial and academic partners, we hope to realize our vision to provide more therapeutic avenues to more patients suffering from inadequately treated disorders and diseases. |
|
